Cooley advised ViewPoint Therapeutics on closing its $35 million Series B funding round led by TPG’s new $2 billion social impact fund, The Rise Fund. The…
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here
